NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ENTA

Enanta Pharmaceuticals Inc

Jul 11 • 04:00PM ET

6.56

Dollar change -0.42
Percentage change -6.02	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD VRTX ABBV BMY MRNA REGN AMGN BIIB NBIX INCY

| Held by: VTI IWM VXF IWN IBB SCHA VTWO DFAS VHT PRFZ

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.54	Insider Own	7.09%	Shs Outstand	21.38M	Perf Week	-16.86%
Market Cap	140.23M	Forward P/E	-	EPS next Y	-3.33	Insider Trans	3.06%	Shs Float	19.86M	Perf Month	-13.46%
Enterprise Value	162.99M	PEG	-	EPS next Q	-0.82	Inst Own	87.57%	Short Float	12.20%	Perf Quarter	45.78%
Income	-96.42M	P/S	2.18	EPS this Y	26.73%	Inst Trans	-8.65%	Short Ratio	14.35	Perf Half Y	21.71%
Sales	64.46M	P/B	1.50	EPS next Y	16.94%	ROA	-26.18%	Short Interest	2.42M	Perf YTD	14.09%
Book/sh	4.38	P/C	0.73	EPS next 5Y	34.36%	ROE	-74.26%	52W High	17.24 -61.94%	Perf Year	-54.57%
Cash/sh	9.05	P/FCF	-	EPS past 3/5Y	-11.88% -	ROIC	-34.83%	52W Low	4.09 60.39%	Perf 3Y	-87.22%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-11.35% -19.91%	Gross Margin	95.09%	Volatility	6.91% 6.48%	Perf 5Y	-87.01%
Dividend TTM	-	EV/Sales	2.53	EPS Y/Y TTM	27.32%	Oper. Margin	-158.40%	ATR (14)	0.44	Perf 10Y	-84.81%
Dividend Ex-Date	-	Quick Ratio	5.29	Sales Y/Y TTM	-11.55%	Profit Margin	-149.57%	RSI (14)	38.98	Recom	1.75
Dividend Gr. 3/5Y	- -	Current Ratio	5.29	EPS Q/Q	27.96%	SMA20	-11.20%	Beta	0.88	Target Price	17.75
Payout	-	Debt/Eq	2.31	Sales Q/Q	-12.48%	SMA50	-0.76%	Rel Volume	1.12	Prev Close	6.98
Employees	131	LT Debt/Eq	1.96	Earnings	May 12 AMC	SMA200	-11.37%	Avg Volume	168.88K	Price	6.56
IPO	Mar 21, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.56% -6.44%	Trades		Volume	189,465	Change	-6.02%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-09-23	Downgrade	JP Morgan	Neutral → Underweight	$14
Aug-08-23	Downgrade	Jefferies	Buy → Hold	$49 → $18
Dec-09-22	Initiated	H.C. Wainwright	Buy	$56
Jul-06-22	Upgrade	Evercore ISI	In-line → Outperform	$62
Jun-01-22	Upgrade	Evercore ISI	Underperform → In-line	$39
Oct-07-21	Initiated	Jefferies	Buy	$95
Sep-09-21	Initiated	SVB Leerink	Mkt Perform	$55
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral	$55
Nov-24-20	Initiated	Evercore ISI	Underperform	$30
Aug-28-20	Resumed	ROTH Capital	Buy	$104
Aug-26-20	Initiated	Piper Sandler	Overweight	$87
Jul-27-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$70
Mar-17-20	Upgrade	Robert W. Baird	Neutral → Outperform	$60
Nov-22-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-26-19	Downgrade	JP Morgan	Neutral → Underweight	$86 → $57
May-24-19	Initiated	Wolfe Research	Outperform	$117
Apr-23-19	Upgrade	Berenberg	Hold → Buy	$80 → $120
Dec-13-18	Initiated	Berenberg	Hold	$80
Jun-06-18	Initiated	ROTH Capital	Buy	$133
Feb-08-18	Downgrade	JP Morgan	Overweight → Neutral

Show Previous Ratings

Jun-11-25 12:34PM	Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus (Business Wire)
May-27-25 07:00AM	Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-22-25 07:00AM	Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting (Business Wire)
May-15-25 09:55AM	Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect? (Zacks)
May-12-25 05:10PM	Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +5.31% -5.77%
04:10PM	Loading…
04:10PM	Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 (Business Wire)
May-08-25 06:20PM	Profound Medical (PROF) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.14%
May-05-25 05:53PM	Enanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to Analysts (Insider Monkey) -8.57% -7.17%
Apr-30-25 08:15AM	Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.18%
Apr-08-25 07:00AM	Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025 (Business Wire)
Mar-17-25 07:00AM	Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (Business Wire) -8.27%
Mar-12-25 07:00AM	Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium (Business Wire)
Feb-14-25 12:00PM	Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Feb-10-25 05:10PM	Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +14.08%
04:11PM	Loading…
04:11PM	Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024 (Business Wire)
Jan-30-25 08:03AM	Shionogis RSV antiviral reduces viral load in Phase II human challenge trial (Clinical Trials Arena)
Jan-08-25 07:00AM	Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-24-24 07:00AM	Enanta Pharmaceuticals to Appeal Ruling Related to '953 Patent Infringement Lawsuit (Business Wire)
Dec-23-24 09:43AM	Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last? (Zacks)
Dec-10-24 12:34PM	Enantas zelicapavir shows promise in paediatric respiratory syncytial virus trial (Clinical Trials Arena)
Dec-09-24 06:30AM	Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) (Business Wire) +11.75%
Dec-06-24 05:00PM	Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV) (Business Wire)
Nov-29-24 01:00AM	Enanta Pharmaceuticals Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility (TipRanks)
Nov-25-24 05:10PM	Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:17PM	Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024 (Business Wire)
Oct-19-24 11:13AM	Enanta Pharmaceuticals (ENTA): Promising Clinical Stage Biotech with Robust Pipeline (Insider Monkey)
Oct-17-24 07:02PM	Millennium Management LLC's Strategic Acquisition of Enanta Pharmaceuticals Shares (GuruFocus.com)
07:53AM	Loading…
Oct-02-24 07:53AM	Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains? (Zacks)
Sep-27-24 06:45AM	J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers (BioPharma Dive)
Sep-26-24 06:00AM	Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV) (Business Wire)
Sep-03-24 07:00AM	Enanta Pharmaceuticals to Participate in Investor Conferences in September (Business Wire)
Aug-09-24 07:27AM	Enanta Pharmaceuticals, Inc. (ENTA): Caligan Partners Top Holding Right Now? (Insider Monkey) -6.75%
Aug-05-24 05:10PM	Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.55%
04:09PM	Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter (Business Wire)
Jul-15-24 10:10AM	Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock? (Zacks)
May-29-24 07:00AM	Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference (Business Wire)
May-07-24 11:43AM	JMP Securities Adjusts Enanta Pharmaceuticals Price Target to $22 From $23, Maintains Market Outperform Rating (MT Newswires) -10.27%
10:24AM	Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call Transcript (Insider Monkey)
07:10AM	Q2 2024 Enanta Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
07:00AM	Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference (Business Wire)
03:07AM	Enanta Pharmaceuticals Inc (ENTA) (Q2 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-06-24 08:59PM	ENTA Stock Earnings: Enanta Pharma Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:47PM	Enanta Pharmaceuticals Reports Fiscal Q2 Results: A Closer Look Against Analyst Expectations (GuruFocus.com)
05:10PM	Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:17PM	Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET (Business Wire)
Apr-30-24 07:10AM	Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
07:00AM	Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer (Business Wire)
Apr-29-24 07:00AM	Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024 (Business Wire) +7.11%
Apr-17-24 07:00AM	Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024 (Business Wire) -8.85%
Mar-06-24 07:00AM	Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference (Business Wire)
Feb-08-24 09:07AM	Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:08AM	Q1 2024 Enanta Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-07-24 05:10PM	Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:59PM	Enanta Pharmaceuticals Inc (ENTA) Reports Fiscal Q1 2024 Results: Royalty Revenue Declines Amid ... (GuruFocus.com)
04:07PM	Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET (Business Wire)
Feb-06-24 07:00AM	Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-31-24 07:00AM	Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023 (Business Wire)
Jan-05-24 03:09AM	Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength? (Zacks)
Jan-04-24 07:00AM	Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +13.80%
Jan-03-24 07:00AM	Enanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-16-23 05:01AM	Insider Sell Alert: Director Terry Vance Sells 15,295 Shares of Enanta Pharmaceuticals Inc (ENTA) (GuruFocus.com)
Dec-13-23 09:55AM	Wall Street Analysts Predict a 108.12% Upside in Enanta Pharmaceuticals (ENTA): Here's What You Should Know (Zacks) +7.90%
Nov-27-23 09:55AM	How Much Upside is Left in Enanta Pharmaceuticals (ENTA)? Wall Street Analysts Think 88.23% (Zacks)
Nov-22-23 07:00AM	Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference (Business Wire) -9.83%
Nov-21-23 08:46AM	Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2023 Earnings Call Transcript (Insider Monkey) +11.52%
07:18AM	Q4 2023 Enanta Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-20-23 04:54PM	Enanta Pharmaceuticals Inc (ENTA) Reports Fiscal Q4 and Full-Year Earnings Amid R&D Focus (GuruFocus.com)
04:18PM	Enanta Pharmaceuticals: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET (Business Wire)
Nov-16-23 11:22PM	MILLENNIUM MANAGEMENT LLC Bolsters Portfolio with Enanta Pharmaceuticals Inc (ENTA) Shares (GuruFocus.com) +5.06%
Nov-13-23 10:00AM	Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for (Zacks)
07:00AM	Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023 (Business Wire)
Oct-30-23 10:01AM	Alpine Immune Sciences, Inc. (ALPN) Surges 8.9%: Is This an Indication of Further Gains? (Zacks) +5.63%
Oct-13-23 07:00AM	Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline (Business Wire)
Sep-17-23 12:00PM	Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference (Business Wire)
Sep-07-23 07:00AM	Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek 2023 (Business Wire)
Sep-01-23 06:51PM	Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600 (PR Newswire) -16.86%
Aug-31-23 07:00AM	Enanta Pharmaceuticals to Participate in Investor Conferences in September (Business Wire)
Aug-13-23 08:08AM	Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade (Simply Wall St.)
Aug-09-23 01:49PM	Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q3 2023 Earnings Call Transcript (Insider Monkey) -9.83%
Aug-08-23 02:23PM	Why Shares of Enanta Pharmaceuticals Are Dropping Tuesday (Motley Fool)
10:42AM	Q3 2023 Enanta Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 05:15PM	Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:07PM	Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot (AP Finance)
04:01PM	Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET (Business Wire)
Jul-31-23 07:00AM	Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023 (Business Wire)
Jun-21-23 08:00PM	ENTA: Lowering target price to $24.00 (Argus Research)
08:36AM	Are Options Traders Betting on a Big Move in Enanta Pharmaceuticals (ENTA) Stock? (Zacks)
Jun-20-23 07:00AM	Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus (Business Wire)
Jun-07-23 07:00AM	Enanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress 2023 (Business Wire)
May-31-23 07:00AM	Enanta Pharmaceuticals to Participate at Jefferies Global Healthcare Conference (Business Wire)
May-11-23 05:05AM	The Petri Dish: Laronde CEO exits after 6 months; Enanta seeks Covid pill partner (American City Business Journals)
May-09-23 07:00AM	Enanta Pharmaceuticals to Participate in Two Investor Conferences in May (Business Wire) -25.66%
May-08-23 05:15PM	Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Luly Jay R.	President and CEO	Feb 12 '25	Buy	5.69	45,000	256,050	846,638	Feb 12 08:09 PM
Kieffer Tara Lynn	Chief Product Strategy Officer	Dec 06 '24	Sale	8.06	2,283	18,401	29,305	Dec 10 05:12 PM
Luu Brendan	Chief Business Officer	Dec 06 '24	Sale	8.06	2,283	18,401	36,047	Dec 10 05:08 PM
Rottinghaus Scott T.	Chief Medical Officer	Dec 06 '24	Sale	8.06	866	6,980	17,918	Dec 10 05:03 PM
Or Yat Sun	Chief Scientific Officer	Dec 06 '24	Sale	8.06	2,591	20,883	369,109	Dec 10 05:00 PM
MELLETT PAUL J	Chief Fin. & Admin Officer	Dec 06 '24	Sale	8.06	2,591	20,883	91,710	Dec 10 04:58 PM
Luly Jay R.	President and CEO	Dec 06 '24	Sale	8.06	5,142	41,445	801,638	Dec 10 04:55 PM
Rottinghaus Scott T.	Chief Medical Officer	Jul 15 '24	Option Exercise	8.99	5,375	48,321	27,092	Jul 15 05:29 PM
Rottinghaus Scott T.	Chief Medical Officer	Jul 15 '24	Sale	17.08	5,375	91,805	21,717	Jul 15 05:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ENTA

Enanta Pharmaceuticals Inc

Upgrade your FINVIZ experience